Premium
Taurine chloramine induces apoptosis in human osteosarcoma cell lines
Author(s) -
Pilz Magdalena,
Holinka Johannes,
Vavken Patrick,
Marian Brigitte,
Krepler Petra
Publication year - 2012
Publication title -
journal of orthopaedic research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.041
H-Index - 155
eISSN - 1554-527X
pISSN - 0736-0266
DOI - 10.1002/jor.22161
Subject(s) - osteosarcoma , apoptosis , acridine orange , fragmentation (computing) , dna fragmentation , cell culture , cancer research , microbiology and biotechnology , cell growth , cell , cytotoxic t cell , medicine , chemistry , programmed cell death , in vitro , biology , biochemistry , genetics , ecology
Although combination of surgery with chemotherapy has noticeably improved the survival rate of osteosarcoma patients, the application of anticancer drugs is still associated with significant adverse reactions, for instance acquisition of drug‐resistant phenotypes, necessitating the development of new chemotherapeutical agents. Therefore, the aim of this study was to research, if taurine chloramine (NCT) induces apoptosis in the osteosarcoma cell lines HOS, MG‐63, and SAOS‐2. Proliferation of osteosarcoma cells was detected with the “EZ4U Cell Proliferation and Cyotoxicity Assay” showing a time‐ and dose‐dependent cytotoxic effect of NCT on these cell lines. After 3 h of incubation all cell lines showed significantly less cells at 5.5 mM NCT solutions, after 6 h at concentrations of 1.1 and 2.2 mM. Acridine‐orange fluorescence nuclear staining showed characteristic features of apoptosis. DNA fragmentation was detected via ELISA, showing significant results for HOS and MG‐63 after 6 h at an NCT concentration of 3.3 mM. Results of JC‐1 mitochondrial FACS analysis presented a significant increase in apoptotic cells after 6 h at 3.3 mM for the tested cell lines. Summarized, the results of this study indicate that NCT is a promising agent in osteosarcoma therapy. © 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:2046–2051, 2012